Raia Drogasil S.A.
RADLY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $38,864,455 | $33,973,790 | $29,067,380 | $24,127,002 |
| % Growth | 14.4% | 16.9% | 20.5% | – |
| Cost of Goods Sold | $27,314,740 | $23,766,426 | $20,257,912 | $16,920,834 |
| Gross Profit | $11,549,715 | $10,207,364 | $8,809,468 | $7,206,168 |
| % Margin | 29.7% | 30% | 30.3% | 29.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1,567,110 | $1,503,526 | $1,249,847 | $912,334 |
| SG&A Expenses | $9,194,671 | $8,192,801 | $7,055,839 | $5,879,153 |
| Sales & Mktg Exp. | $7,627,561 | $6,689,275 | $5,805,992 | $4,966,819 |
| Other Operating Expenses | -$12,127 | -$65,926 | $106,635 | $0 |
| Operating Expenses | $9,182,544 | $8,126,875 | $6,975,303 | $5,831,670 |
| Operating Income | $2,367,171 | $2,080,489 | $1,479,919 | $1,222,391 |
| % Margin | 6.1% | 6.1% | 5.1% | 5.1% |
| Other Income/Exp. Net | -$951,460 | -$863,796 | -$646,115 | -$339,683 |
| Pre-Tax Income | $1,415,711 | $1,216,693 | $1,193,209 | $987,262 |
| Tax Expense | $206,508 | $129,550 | $178,241 | $223,129 |
| Net Income | $1,197,694 | $1,054,973 | $996,112 | $751,934 |
| % Margin | 3.1% | 3.1% | 3.4% | 3.1% |
| EPS | 0.73 | 0.62 | 0.58 | 0.44 |
| % Growth | 17.7% | 6.9% | 31.8% | – |
| EPS Diluted | 0.72 | 0.62 | 0.58 | 0.44 |
| Weighted Avg Shares Out | 1,649,227 | 1,695,194 | 1,713,559 | 1,715,242 |
| Weighted Avg Shares Out Dil | 1,654,988 | 1,695,194 | 1,719,821 | 1,719,936 |
| Supplemental Information | – | – | – | – |
| Interest Income | $24 | $45,908 | $487 | $64 |
| Interest Expense | $812,719 | $737,787 | $292,690 | $228,230 |
| Depreciation & Amortization | $911,965 | $797,690 | $1,473,350 | $1,292,310 |
| EBITDA | $3,140,395 | $2,752,170 | $2,452,598 | $2,630,375 |
| % Margin | 8.1% | 8.1% | 8.4% | 10.9% |